Morningstar

Kenvue Inc KVUE

Morningstar Rating
Unlock
Stock XNYS Rating as of
$18.98 −0.04 (0.21%)
View Full Chart
As of Delayed Price Pre-Open: $18.91 −0.07

Company Report

View Archive

Kenvue To Be Acquired by Kimberly-Clark To Create a Personal Care Giant

Keonhee Kim

Kenvue is the world’s largest pure-play consumer health company by revenue, generating over $15 billion in annual sales. The former consumer segment of Johnson & Johnson spun off and went public in May 2023. We expect Kenvue to focus on its 15 priority brands (including Tylenol, Nicorette, Listerine, and Zyrtec) to drive future growth. We forecast the firm to spend roughly 3% of sales on research and development, on par with some of its wide-moat competitors, to launch innovative products.

Read Full Report

Price vs Fair Value

View History
KVUE is trading at a LOCK|&DBFpN premium.
Price
$18.98
Fair Value
$S
Uncertainty
LOCK|#<R
1-Star Price
LOCK|.Bwy
5-Star Price
LOCK|.%
Economic Moat
LOCK|?Jx
Capital Allocation
LOCK|YNDdD@?

Bulls Say, Bears Say

Bulls

With autonomy from its former parent, Kenvue can allocate resources to best fit its needs and expand the business.

Bears

Negative press on Tylenol, Kenvue's biggest product by revenue, from the White House could adversely affect demand and hurt future earnings potential.

Show More

News

View All

Articles & Videos

Trading Information

Previous Close Price
$19.02
Day Range
$18.85–19.36
52-Week Range
$14.02–22.87
Bid/Ask
$18.91 / $19.09
Shares Outstanding
1.92B
Market Cap
$36.44B
Volume/Avg
173 / 20M

Key Statistics

Price/Earnings (Normalized)
16.36
Price/Sales
2.39
Dividend Yield (Trailing)
4.37%
Dividend Yield (Forward)
4.37%
Total Yield
4.74%

Company Profile

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
Sector
Consumer Defensive
Industry
Household & Personal Products
Stock Style Box
Mid Value
Total Number of Employees
22,000
Website
https://www.kenvue.com

Competitors

Valuation

View More
Metric
KVUE
KMB
PG
Price/Earnings (Normalized)
 16.3617.7321.95
Price/Book Value
 3.4420.026.43
Price/Sales
 2.392.184.20
Price/Cash Flow
 15.6510.8121.08
Price/Earnings
KVUE
KMB
PG

Financial Strength

Metric
KVUE
KMB
PG
Quick Ratio
 0.680.370.49
Current Ratio
 0.980.770.73
Interest Coverage
 6.049.6325.08
Quick Ratio
KVUE
KMB
PG

Profitability

Metric
KVUE
KMB
PG
Return on Assets (Normalized)
 7.21%11.00%13.35%
Return on Equity (Normalized)
 18.37%132.33%31.88%
Return on Invested Capital (Normalized)
 11.44%23.00%19.30%
Return on Assets
KVUE
KMB
PG

Household & Personal Products Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Procter & Gamble Co
PG
LOCK|$Ns$lXsLOCK|xR>$349B
 L'Oreal SA
LRLCF
—LOCK|PG>$233B
 Unilever PLC ADR
UL
LOCK|lH%Lp$&LOCK|fW>$136B
 Colgate-Palmolive Co
CL
LOCK|k@#>l<c@LOCK|tY$74B
 Reckitt Benckiser Group PLC ADR
RBGLY
LOCK|rK>>?YhLOCK|?%m$44B
 Kimberly-Clark Corp
KMB
LOCK|Qh%WY>LOCK|#ZPy$36B
 The Estee Lauder Companies Inc Class A
EL
LOCK|$m%p#>gLOCK|prJ$30B
 Church & Dwight Co Inc
CHD
LOCK|kjP!x@LOCK|w#$23B
 Clorox Co
CLX
LOCK|x##wm&!LOCK|$^@$12B

Sponsor Center